← Back to Clinical Trials
Recruiting NCT06866652

NCT06866652 Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06866652
Status Recruiting
Phase
Sponsor Institut de Myologie, France
Condition Myasthenia Gravis
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2026-04-08
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2026-04-08 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 * Confirmed diagnosis of autoimmune MG * Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score * Signed consent form * Affiliated to or beneficiary of a social security scheme Exclusion Criteria: * Known Pregnancy * Known respiratory disorder (other than MG) * Recent (within past 4 weeks) respiratory infection * Current MG crisis or exacerbation (necessitating increase in MG medication \&/or hospital admission) * No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score * Severe cognitive impairment/guardianship

Frequently Asked Questions

Who can join the NCT06866652 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06866652 currently recruiting?

Yes, NCT06866652 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institut de Myologie, France to inquire about joining.

Where is the NCT06866652 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT06866652 clinical trial?

NCT06866652 is sponsored by Institut de Myologie, France. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology